Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The erythropoietin-producing hepatocellular (Eph) family of receptor tyrosine kinases regulates a multitude of physiological and pathological processes. Despite the numerous possible research and therapeutic applications of agents capable of modulating Eph receptor function, no small molecule inhibitors targeting the extracellular domain of these receptors have been identified. We have performed a high throughput screen to search for small molecules that inhibit ligand binding to the extracellular domain of the EphA4 receptor. This yielded a 2,5-dimethylpyrrolyl benzoic acid derivative able to inhibit the interaction of EphA4 with a peptide ligand as well as the natural ephrin ligands. Evaluation of a series of analogs identified an isomer with similar inhibitory properties and other less potent compounds. The two isomeric compounds act as competitive inhibitors, suggesting that they target the high affinity ligand-binding pocket of EphA4 and inhibit ephrin-A5 binding to EphA4 with K(i) values of 7 and 9 mum in enzyme-linked immunosorbent assays. Interestingly, despite the ability of each ephrin ligand to promiscuously bind many Eph receptors, the two compounds selectively target EphA4 and the closely related EphA2 receptor. The compounds also inhibit ephrin-induced phosphorylation of EphA4 and EphA2 in cells, without affecting cell viability or the phosphorylation of other receptor tyrosine kinases. Furthermore, the compounds inhibit EphA4-mediated growth cone collapse in retinal explants and EphA2-dependent retraction of the cell periphery in prostate cancer cells. These data demonstrate that the Eph receptor-ephrin interface can be targeted by inhibitory small molecules and suggest that the two compounds identified will be useful to discriminate the activities of EphA4 and EphA2 from those of other co-expressed Eph receptors that are activated by the same ephrin ligands. Furthermore, the newly identified inhibitors represent possible leads for the development of therapies to treat pathologies in which EphA4 and EphA2 are involved, including nerve injuries and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling
Murai, K. K., Nguyen, L. N., Irie, F., Yamaguchi, Y., & Pasquale, E. B. (2003) · Nature Neuroscience · doi:10.1038/nn994 · Cited by 516
Self-citation
Cited by
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Self-citationTherapeutic targeting of EPH receptors and their ligands
Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4175 · Cited by 341
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans
Van Hoecke, A., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K. A., Laird, A. S., Peeters, E., Philips, T., Goris, A., Dubois, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2901 · Cited by 303
Fu, A. K. Y., Hung, K.-W., Huang, H., Gu, S., Shen, Y., Cheng, E. Y. L., Ip, F. C. F., Huang, X., Fu, W.-Y., & Ip, N. Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405803111 · Cited by 201
“Intriguingly, blockade of EphA4 or Cdk5 signaling by [2,5- dimethylpyrrolyl benzoic acid (Cpd1)] (28) or [roscovitine (Ros)] (16), respectively, also attenuated the Aβ-stimulated reduction in neurotransmission (Fig.”
BackgroundMethodInfluentialArkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
EphA2 is an epithelial cell pattern recognition receptor for fungal β-glucans
Swidergall, M., Solis, N. V., Lionakis, M. S., & Filler, S. G. (2017) · Nature Microbiology · doi:10.1038/s41564-017-0059-5 · Cited by 167
“…of the various inhibitors, the host cells were treated for 1 h prior to stimulation or infection with 2.5 μM dasatinib 30 , 400 μM EphA2 antagonist, a 2,5-dimethylpyrrolyl benzoic acid derivative 15,31 , 50 μM Stat3 inhibitor S31-201 32 , 1μM gefitinib 16 , 3 μg/ml dectin-1 mAb (R&D Systems) 33 .”
InfluentialEphA4 Activation of c-Abl Mediates Synaptic Loss and LTP Blockade Caused by Amyloid-β Oligomers
M. Vargas, L., Leal, N., Estrada, L. D., González, A., Serrano, F., Araya, K., Gysling, K., Inestrosa, N. C., Pasquale, E. B., & Alvarez, A. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092309 · Cited by 85
Self-citationDe novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway
Fritsche‐Guenther, R., Noske, A., Ungethüm, U., Kuban, R., Schlag, P. M., Tunn, P., Karle, J., Krenn, V., Dietel, M., & Sers, C. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03713.x · Cited by 69
Ephrin‐ A 1‐ EphA4 signaling negatively regulates myelination in the central nervous system
Harboe, M., Torvund‐Jensen, J., Kjaer‐Sorensen, K., & Laursen, L. S. (2018) · Glia · doi:10.1002/glia.23293 · Cited by 56
“To further delineate the mechanism by which EphA4 signaling may regulate myelination, co-cultures were treated either with a low-molecular weight antagonist (C1) of EphA signaling (Noberini et al., 2008) or doxazosin (Dox), which in addition to its effect on the alpha1-adrenergic receptor is also an agonist of EphA si…”
BackgroundAntibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination
Syed, Y. A., Zhao, C., Mahad, D., Möbius, W., Altmann, F., Foss, F., Sentürk, A., Acker-Palmer, A., Lubec, G., Lilley, K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1521-1 · Cited by 50
“Small molecules and other pharmacological agents acting at the ligand-receptor and receptor-RTK levels are currently being developed [39].”
BackgroundLamberto, I., Qin, H., Noberini, R., Premkumar, L., Bourgin, C., Riedl, S. J., Song, J., & Pasquale, E. B. (2012) · Biochemical Journal · doi:10.1042/bj20120408 · Cited by 48
Self-citationThe Role of Ephs and Ephrins in Memory Formation
Dines, M., & Lamprecht, R. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv106 · Cited by 47
Qin, H., Lim, L., & Song, J. (2012) · BMC Biophysics · doi:10.1186/2046-1682-5-2 · Cited by 23
Lefort, R. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0328-4 · Cited by 17
Huan, X., Shi, J., Lim, L., Mitra, S., Zhu, W., Qin, H., Pasquale, E. B., & Song, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074040 · Cited by 16
“The unique ability of the Eph receptor LBD to use the same fold to bind ephrins, antagonistic peptides, small molecules [12,22,23] and the MSP domain of VAPB [24,25] makes them an attractive model system for deciphering the structural and dynamic principles governing protein-ligand interactions.”
BackgroundSelf-citation
Metadata
- Authors
- Noberini, R., Koolpe, M., Peddibhotla, S., Dahl, R., Su, Y., Cosford, N. D. P., Roth, G. P., & Pasquale, E. B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 283
- Issue
- 43
- Pages
- 29461-29472
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2120376007
- Cited by
- 135
- References
- 3
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.